Blog
RSS FeedPosted by Michael Wonder on 02 Sep 2023
Additional COVID-19 vaccine dose recommended for adults 75 years and over
1 September 2023 - The Australian Government has accepted advice from the Australian Technical Advisory Group on Immunisation (ATAGI) that all ...
Posted by Michael Wonder on 02 Sep 2023
Why you cannot win with private health insurance, thanks to a 50 year old quirk
1 September 2023 - In a dimly lit room, a masseur performs an incantation in a baritone voice, slapping fish ...
Posted by Michael Wonder on 01 Sep 2023
Department publishes revised agenda for November 2023 PBAC meeting
1 September 2023 - The initial agenda for the November 2023 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 Sep 2023
Pharmacy Guild suspends campaign as 60 day dispensing begins
1 September 2023 - The Pharmacy Guild of Australia has agreed to suspend its campaign against 60 day dispensing after ...
Posted by Michael Wonder on 01 Sep 2023
Department publishes revised agenda for the September 2023 PBAC meeting
31 August 2023 - The agenda for this month's intracycle meeting has been updated. ...
Posted by Michael Wonder on 01 Sep 2023
Celltrion applies for Australian approval for Stelara biosimilar
31 August 2023 - Celltrion said it has completed a marketing authorisation application for CT-P43, a biosimilar referencing Stelara (ustekinumab) ...
Posted by Michael Wonder on 31 Aug 2023
Schedule of Pharmaceutical Benefits - 1 September 2023
1 September 2023 - The September 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Aug 2023
Updates to the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023
30 August 2023 - The agenda for the HTA Review Reference Committee meeting on 25 August 2023 is now available. ...
Posted by Michael Wonder on 29 Aug 2023
Australia knocks back application for diabetes drug that could overshadow Ozempic
29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...
Posted by Michael Wonder on 28 Aug 2023
Efficient Funding of Chemotherapy Review – final report
28 August 2023 - The final report of the Efficient Funding of Chemotherapy Review is now available. ...
Posted by Michael Wonder on 26 Aug 2023
Agenda for the September 2023 PBAC intracycle meeting
25 August 2023 - The agenda for the September 2023 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 25 Aug 2023
Public Summary Documents – May 2023 PBAC meeting
25 August 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2023 PBAC ...
Posted by Michael Wonder on 23 Aug 2023
Updates to the Health Technology Assessment Policy and Methods Review including consultation 1 responses published
23 August 2023 - Responses to the first public consultation for the HTA Review (Consultation 1) have now been published ...
Posted by Michael Wonder on 21 Aug 2023
Recommendations made by the PBAC (July 2023)
18 August 2023 - Recommendations made by the PBAC in July 2023 relating to the listing of medicines on the ...
Posted by Michael Wonder on 18 Aug 2023
Estimating overall survival in people receiving PBS listed cancer medicines in Australian clinical practice
18 August 2023 - In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for ...